APOE
About APOE
APOE commonly occurs as ε2, ε3 and ε4 alleles. ε4 is associated with increased risk of late-onset Alzheimer’s disease, but many carriers never develop the disease and people without ε4 can still develop it.
GENETIC RISK INFORMATION
Understand genetic associations with late-onset Alzheimer’s disease and what a result cannot determine.
APOE and TOMM40 results provide reference information about associations observed at population level. They do not determine whether a person currently has dementia, whether they will develop it, or the age at which symptoms might begin.


ABOUT THE INFORMATION
APOE and TOMM40 results are genetic association information rather than a diagnosis.
APOE
APOE commonly occurs as ε2, ε3 and ε4 alleles. ε4 is associated with increased risk of late-onset Alzheimer’s disease, but many carriers never develop the disease and people without ε4 can still develop it.
TOMM40
TOMM40 lies near APOE in a region with strong linkage. Associations with age at onset and cognitive phenotypes are under study, but findings about predictive value independent of APOE are inconsistent.
BEFORE TESTING
PROCESS
FAQ
No. It is associated with risk, not certainty. Age, other genes, health and environment also matter.
No. Cognitive symptoms require medical assessment, which may include history, cognitive testing, imaging and other evaluation.
CONSULTATION
Genetic information can affect the individual and biological relatives. Review the limitations and data handling before testing.